RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aurinia Pharmaceuticals Stock

Aurinia Pharmaceuticals ROCE 2024

Aurinia Pharmaceuticals ROCE

-0.24

Ticker

AUPH

ISIN

CA05156V1022

WKN

A1W7D4

In 2024, Aurinia Pharmaceuticals's return on capital employed (ROCE) was -0.24, a -11.77% increase from the -0.27 ROCE in the previous year.

Aurinia Pharmaceuticals Aktienanalyse

What does Aurinia Pharmaceuticals do?

Aurinia Pharmaceuticals Inc is a biopharmaceutical company that was founded in Canada in 1993. The company specializes in developing therapy options for autoimmune diseases, particularly the treatment of Lupus Nephritis, a condition where the immune system mistakenly attacks the body's own cells and damages the kidneys. Aurinia specializes in the field of biologic medications, which are based on proteins that naturally occur in the human body. These medications are used to modulate the immune system and "suppress" specific cells that trigger autoimmune diseases. Aurinia's main product is Voclosporin, an orally administered drug specifically developed for the treatment of Lupus Nephritis. Clinical trials have shown promising results, and Voclosporin received approval from the US FDA in 2020. Voclosporin is now successfully used in several countries worldwide. Aurinia also conducts research and development in other areas of autoimmune diseases. Another potential application is the treatment of Vogt-Koyanagi-Harada disease, a rare eye condition also attributed to autoimmune diseases. Aurinia's business model is based on developing new therapies that address the medical needs of patients with autoimmune diseases. The company focuses on close collaboration with medical professionals, patients and their families, as well as regulatory authorities. Aurinia has also formed partnerships with other companies and non-profit organizations to support its research and development and enhance access to its products in different countries. Aurinia's success relies on the extensive experience and expertise of its employees in biotechnological research, development and manufacturing of biologic medications, as well as its close partnerships with world-leading physicians in the field of autoimmune diseases. The company is committed to constantly improving the quality of its products and services to enhance patients' quality of life and effectively treat their disease. Overall, Aurinia Pharmaceuticals is a company dedicated to developing innovative therapies for autoimmune diseases, particularly for the treatment of Lupus Nephritis. The company strives to meet the medical needs of patients, their families, and medical professionals while also improving the entire ecosystem of medical care in this field. Aurinia's goal is to provide patients with better and more effective therapies and treatments to improve their health and well-being. Aurinia Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Aurinia Pharmaceuticals's Return on Capital Employed (ROCE)

Aurinia Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Aurinia Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Aurinia Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Aurinia Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Aurinia Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of Aurinia Pharmaceuticals this year?

The ROCE of Aurinia Pharmaceuticals is -0.24 undefined this year.

How has the ROCE (Return on Capital Employed) of Aurinia Pharmaceuticals developed compared to the previous year?

The ROCE of Aurinia Pharmaceuticals has increased by -11.77% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Aurinia Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Aurinia Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Aurinia Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Aurinia Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Aurinia Pharmaceuticals impact the company?

An increase in the ROCE of Aurinia Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Aurinia Pharmaceuticals affect the company?

A decrease in ROCE of Aurinia Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Aurinia Pharmaceuticals?

Some factors that can affect Aurinia Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Aurinia Pharmaceuticals so important for investors?

The ROCE of Aurinia Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Aurinia Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Aurinia Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Aurinia Pharmaceuticals pay?

Over the past 12 months, Aurinia Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aurinia Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aurinia Pharmaceuticals?

The current dividend yield of Aurinia Pharmaceuticals is .

When does Aurinia Pharmaceuticals pay dividends?

Aurinia Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aurinia Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aurinia Pharmaceuticals located?

Aurinia Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aurinia Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aurinia Pharmaceuticals from 9/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did Aurinia Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of Aurinia Pharmaceuticals in the year 2023?

In the year 2023, Aurinia Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aurinia Pharmaceuticals pay out the dividend?

The dividends of Aurinia Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aurinia Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aurinia Pharmaceuticals

Our stock analysis for Aurinia Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aurinia Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.